Unibest

Pharmaceutical intermediates

Nilotinib Intermediates

3 pharmaceutical intermediates for Nilotinib. Indication: Chronic Myeloid Leukemia (CML); Accelerated Phase of Myeloid Leukemia; Chronic Myelogenous Leukemia (CML).

提交项目All intermediates

About Nilotinib

Originator
Novartis Pharmaceuticals Corp
Indication
Chronic Myeloid Leukemia (CML); Accelerated Phase of Myeloid Leukemia; Chronic Myelogenous Leukemia (CML)
Approved Date
10/29/2007

Available intermediates

3 intermediates currently listed for Nilotinib. Request specifications, documentation or a quotation for any item below.

Nilotinib intermediates
Product NameCAS No.Molecular FormulaPhysical Properties
3-[(Aminoiminomethyl)amino] -4-methylbenzoic acid ethyl ester mononitrate641569-96-2//
4-Methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]benzoic acid641569-94-0//
3-(4-Methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)aniline641571-11-1//

Other programs under N

Nafamostat mesylateNebivolol HydrochlorideNemorexantNeratinib/ PyrotinibNintedanib EsylateNiraparib

Building toward Nilotinib?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目 联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →